CIFoundry

Cardiology AI tools

Cardiology AI reads ECGs, echocardiograms and cardiac imaging. It finds hidden disease such as low ejection fraction or amyloidosis, automates measurements and supports heart-failure and arrhythmia care.

72
tools listed
47
FDA-cleared
13
with named health-system users
4
Epic-integrated

Well-documented cardiology tools

Not a ranking. Shown A–Z.

How we picked these

Tools are picked automatically from four public signals recorded in each listing: FDA clearance, De Novo or approval; health systems named as users in news reports; a linked published study; and Epic integration. A tool needs at least 2 of the 4 to appear. Tools with more signals, then more reported health-system users, come first, until about 8 are shown. Tools that tie are shown together or not at all (never more than 10), so no tool is picked over another by name. “Well-documented” describes the public record, not clinical quality. This list is based on information recorded in each listing; a tool's absence doesn't mean it lacks these qualities. No one can pay to appear here, and advertising never affects this list.

Evaluating a cardiology AI tool? Use our checklist

What physicians and administrators look for, evidence to ask for, how to test it locally, red flags and questions for the vendor. Jump straight to the tool type:

All 72 cardiology AI tools

Listed A–Z. Listing is free, and no one can pay to change the order.

Cardiology
FDA Cleared

Anumana ECG-AI LEF (Low Ejection Fraction)

Anumana, Inc. (in partnership with Mayo Clinic)

Anumana ECG-AI LEF is an FDA 510(k)-cleared software-as-a-medical-device that applies a deep learning algorithm to a standard 12-lead ECG to screen for low left ventricular ejection fraction (LVEF <= 40%), a key indicator of heart failure. Developed with Mayo Clinic and trained on over 100,000 ECG-echocardiogram pairs, it achieved an AUROC of 0.92 (84.5% sensitivity, 83.6% specificity) in multisite validation. In the pragmatic EAGLE randomized trial it improved diagnosis of low EF by ~31% without increasing overall echocardiography use. Anumana has since added FDA-cleared 12-lead ECG algorithms for pulmonary hypertension (K252360, March 2026) and cardiac amyloidosis (K253801, April 2026).

  • FDAon record
  • Epicnot on record
  • Named userson record
  • Studyon record
ECGdeep learningheart failure+4

Get weekly updates for Cardiology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

How to evaluate cardiology AI

Regulatory status

Check whether the tool is FDA-cleared for the exact use you plan, or is a non-device or research tool. Every listing links to the FDA record where one exists.

Evidence

Look for peer-reviewed validation, ideally in patients and settings like yours, and ask vendors how performance is monitored after go-live.

Integration

Confirm how it fits your EHR and workflow (Epic, PACS, FHIR) and who does the integration work.

Peer adoption

See which health systems already use it and ask peers in the forum about real-world results.

Can't find the right fit? Browse builder firms that build custom cardiology AI, or compare tools side by side.

Other specialties